Course Description
About AAPP Toolkits
AAPP toolkits highlight both the evidence base available as well as strategies of clinical decision making used by expert psychiatric pharmacist clinicians. The content reflects the views and practice of the authors as substantiated with evidence-based facts as well as opinion and experience. Toolkits are peer reviewed by psychiatric pharmacists. Authors and AAPP review and update toolkits annually and strive to use up-to-date, non-stigmatizing language. Terminology does evolve rapidly and often regionally such that there may be differences between reader experiences and expectations and those of the author(s). AAPP members receive complimentary, continuous access to toolkits. Non-members can purchase for a fee for a period of 3 months.
The nation’s drug overdose epidemic continues to change and become worse. The epidemic affects every state and now is driven by illicit fentanyl, fentanyl analogs, methamphetamine, and cocaine, often in combination or in adulterated forms. More than 107,000 deaths were reported in the United States between December 2020 to December 2021. To respond to this epidemic, the CDC recommends expanding treatment access to life-saving and effective medications for opioid use disorder (MOUD), including buprenorphine, methadone, and naltrexone. This free toolkit provides tips and guidance in the following areas of Buprenorphine Initiation:
- Buprenorphine Treatment
- Traditional Buprenorphine Initiation
- Low Dose Overlap Initiation
- Special Populations
- Harm Reduction
- Helpful Resources
- References